About us
Fenlai Tan, MD, PhD
CEO
Specialized in clinical development and commercialization of anticancer drugs;
2007-2018: Co-Founder, Board of Director, CMO, Betta Pharmaceutical Co., Ltd, which went public in 2016;
Successful led the clinical development, strategic in-licensing, and NDA of 4 anticancer drugs:
Led the clinical development of Phase 1/2/3/4 clinical study of Icotinib for EGFR+NSCLC in China;
Led the in-licensing and global phase 3 clinical study of Ensartinib (ALKi) (approved in China since 2020), and Vorolaninib (VEGFRi);
Led the strategic in-licensing and NDA filing of MIL60 (anti-VEGF mAb);
Extensive experience in BD, sale/marketing, capital market/IPO, business operation and management .